Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 668

1.

Correction: Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2018 Oct 26;13(10):e0206729. doi: 10.1371/journal.pone.0206729. eCollection 2018.

2.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

3.

Response to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".

Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ.

Br J Cancer. 2018 Oct;119(9):1170. doi: 10.1038/s41416-018-0177-8. Epub 2018 Oct 17. No abstract available.

PMID:
30327568
4.

Effectiveness of the Malnutrition eLearning Course for Global Capacity Building in the Management of Malnutrition: Cross-Country Interrupted Time-Series Study.

Choi S, Yuen HM, Annan R, Pickup T, Pulman A, Monroy-Valle M, Aduku NEL, Kyei-Boateng S, Velásquez Monzón CI, Portillo Sermeño CE, Penn A, Ashworth A, Jackson AA.

J Med Internet Res. 2018 Oct 3;20(10):e10396. doi: 10.2196/10396.

5.

Author Correction: Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Aug 21;8(1):12771. doi: 10.1038/s41598-018-30922-8.

6.

Dealing with serious concerns: catch the three wise monkeys.

Ashworth AJ.

BMJ. 2018 Aug 7;362:k3419. doi: 10.1136/bmj.k3419. No abstract available.

PMID:
30087109
7.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Jul 26;174(3):758-769.e9. doi: 10.1016/j.cell.2018.06.039. Epub 2018 Jul 19. Erratum in: Cell. 2018 Oct 18;175(3):889.

8.

Chemosensitivity profiling of osteosarcoma tumour cell lines identifies a model of BRCAness.

Holme H, Gulati A, Brough R, Fleuren EDG, Bajrami I, Campbell J, Chong IY, Costa-Cabral S, Elliott R, Fenton T, Frankum J, Jones SE, Menon M, Miller R, Pemberton HN, Postel-Vinay S, Rafiq R, Selfe JL, von Kriegsheim A, Munoz AG, Rodriguez J, Shipley J, van der Graaf WTA, Williamson CT, Ryan CJ, Pettitt S, Ashworth A, Strauss SJ, Lord CJ.

Sci Rep. 2018 Jul 13;8(1):10614. doi: 10.1038/s41598-018-29043-z. Erratum in: Sci Rep. 2018 Aug 21;8(1):12771.

9.

Reprogramming human T cell function and specificity with non-viral genome targeting.

Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, Hiatt J, Saco J, Krystofinski P, Li H, Tobin V, Nguyen DN, Lee MR, Putnam AL, Ferris AL, Chen JW, Schickel JN, Pellerin L, Carmody D, Alkorta-Aranburu G, Del Gaudio D, Matsumoto H, Morell M, Mao Y, Cho M, Quadros RM, Gurumurthy CB, Smith B, Haugwitz M, Hughes SH, Weissman JS, Schumann K, Esensten JH, May AP, Ashworth A, Kupfer GM, Greeley SAW, Bacchetta R, Meffre E, Roncarolo MG, Romberg N, Herold KC, Ribas A, Leonetti MD, Marson A.

Nature. 2018 Jul;559(7714):405-409. doi: 10.1038/s41586-018-0326-5. Epub 2018 Jul 11.

PMID:
29995861
10.

Global meta-analysis reveals agro-grassland productivity varies based on species diversity over time.

Ashworth AJ, Toler HD, Allen FL, Augé RM.

PLoS One. 2018 Jul 10;13(7):e0200274. doi: 10.1371/journal.pone.0200274. eCollection 2018.

11.

Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial.

Danilenko M, Stamp E, Stocken DD, Husain A, Zangarini M, Cranston A, Stones R, Sinclair N, Hodgson K, Bowett SA, Roblin D, Traversa S, Plummer R, Veal G, Langtry JAA, Ashworth A, Burn J, Rajan N.

JAMA Dermatol. 2018 Aug 1;154(8):913-921. doi: 10.1001/jamadermatol.2018.1610.

12.

Synthetic lethal therapies for cancer: what's next after PARP inhibitors?

Ashworth A, Lord CJ.

Nat Rev Clin Oncol. 2018 Sep;15(9):564-576. doi: 10.1038/s41571-018-0055-6. Review.

PMID:
29955114
13.

Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets.

Krastev DB, Pettitt SJ, Campbell J, Song F, Tanos BE, Stoynov SS, Ashworth A, Lord CJ.

Nat Commun. 2018 May 22;9(1):2016. doi: 10.1038/s41467-018-04466-4.

14.

Reply to 'Comment on 'Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study".

Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ.

Br J Cancer. 2018 May;118(11):1537. doi: 10.1038/s41416-018-0092-z. Epub 2018 May 17. No abstract available.

PMID:
29769747
15.

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.

Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ.

Nat Commun. 2018 May 10;9(1):1849. doi: 10.1038/s41467-018-03917-2.

16.

Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, Brown R, Chan S, Dowsett M, Flanagan JM, Fox L, Grigoriadis A, Gutin A, Harper-Wynne C, Hatton MQ, Hoadley KA, Parikh J, Parker P, Perou CM, Roylance R, Shah V, Shaw A, Smith IE, Timms KM, Wardley AM, Wilson G, Gillett C, Lanchbury JS, Ashworth A, Rahman N, Harries M, Ellis P, Pinder SE, Bliss JM.

Nat Med. 2018 May;24(5):628-637. doi: 10.1038/s41591-018-0009-7. Epub 2018 Apr 30.

17.

Moving toward uniform and evidence-based practice of radiotherapy for management of cervical cancer in Ontario, Canada.

Shahid N, Craig T, Westerland M, Ashworth A, Ang M, D'Souza D, Sankreacha R, Fyles A, Milosevic M, Kong I; Cancer Care Ontario Radiation Treatment Gynecologic Oncology Community of Practice.

Brachytherapy. 2018 Jul - Aug;17(4):660-666. doi: 10.1016/j.brachy.2018.03.003. Epub 2018 Apr 19.

PMID:
29681500
18.

Effects of Land-Applied Ammonia Scrubber Solutions on Yield, Nitrogen Uptake, Soil Test Phosphorus, and Phosphorus Runoff.

Martin JW, Moore PA, Li H, Ashworth AJ, Miles DM.

J Environ Qual. 2018 Mar;47(2):263-269. doi: 10.2134/jeq2017.09.0383.

PMID:
29634801
19.

Perioperative Extracorporeal Cardiopulmonary Resuscitation: The Defibrillator of the 21st Century?: A Case Report.

Charlesworth M, Barker JM, Greenhalgh D, Ashworth AD.

A A Pract. 2018 Aug 15;11(4):87-89. doi: 10.1213/XAA.0000000000000742.

PMID:
29634540
20.

Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.

Ghoussaini M, Edwards SL, Michailidou K, Nord S, Cowper-Sal Lari R, Desai K, Kar S, Hillman KM, Kaufmann S, Glubb DM, Beesley J, Dennis J, Bolla MK, Wang Q, Dicks E, Guo Q, Schmidt MK, Shah M, Luben R, Brown J, Czene K, Darabi H, Eriksson M, Klevebring D, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Lambrechts D, Thienpont B, Neven P, Wildiers H, Broeks A, Van't Veer LJ, Rutgers EJT, Couch FJ, Olson JE, Hallberg E, Vachon C, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Peto J, Dos-Santos-Silva I, Gibson L, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Hall P, Li J, Liu J, Humphreys K, Kang D, Choi JY, Park SK, Noh DY, Matsuo K, Ito H, Iwata H, Yatabe Y, Guénel P, Truong T, Menegaux F, Sanchez M, Burwinkel B, Marme F, Schneeweiss A, Sohn C, Wu AH, Tseng CC, Van Den Berg D, Stram DO, Benitez J, Pilar Zamora M, Perez JIA, Menéndez P, Shu XO, Lu W, Gao YT, Cai Q, Cox A, Cross SS, Reed MWR, Andrulis IL, Knight JA, Glendon G, Tchatchou S, Sawyer EJ, Tomlinson I, Kerin MJ, Miller N, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Lindblom A, Margolin S, Teo SH, Yip CH, Lee DSC, Wong TY, Hooning MJ, Martens JWM, Collée JM, van Deurzen CHM, Hopper JL, Southey MC, Tsimiklis H, Kapuscinski MK, Shen CY, Wu PE, Yu JC, Chen ST, Alnæs GG, Borresen-Dale AL, Giles GG, Milne RL, McLean C, Muir K, Lophatananon A, Stewart-Brown S, Siriwanarangsan P, Hartman M, Miao H, Buhari SABS, Teo YY, Fasching PA, Haeberle L, Ekici AB, Beckmann MW, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Swerdlow A, Ashworth A, Orr N, Schoemaker MJ, García-Closas M, Figueroa J, Chanock SJ, Lissowska J, Simard J, Goldberg MS, Labrèche F, Dumont M, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Brauch H, Brüning T, Koto YD, Radice P, Peterlongo P, Bonanni B, Volorio S, Dörk T, Bogdanova NV, Helbig S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Devilee P, Tollenaar RAEM, Seynaeve C, Van Asperen CJ, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Slager S, Toland AE, Ambrosone CB, Yannoukakos D, Sangrajrang S, Gaborieau V, Brennan P, McKay J, Hamann U, Torres D, Zheng W, Long J, Anton-Culver H, Neuhausen SL, Luccarini C, Baynes C, Ahmed S, Maranian M, Healey CS, González-Neira A, Pita G, Rosario Alonso M, Álvarez N, Herrero D, Tessier DC, Vincent D, Bacot F, de Santiago I, Carroll J, Caldas C, Brown MA, Lupien M, Kristensen VN, Pharoah PDP, Chenevix-Trench G, French JD, Easton DF, Dunning AM.

Nat Commun. 2018 Apr 10;9:16193. doi: 10.1038/ncomms16193.

21.

Invasive pulmonary aspergillosis is associated with adverse clinical outcomes in critically ill patients receiving veno-venous extracorporeal membrane oxygenation.

Rodriguez-Goncer I, Thomas S, Foden P, Richardson MD, Ashworth A, Barker J, Geraghty CG, Muldoon EG, Felton TW.

Eur J Clin Microbiol Infect Dis. 2018 Jul;37(7):1251-1257. doi: 10.1007/s10096-018-3241-7. Epub 2018 Apr 6.

22.

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ.

Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603.

PMID:
29610289
23.

Multidisciplinary Clinics in Lung Cancer Care: A Systematic Review.

Stone CJL, Vaid HM, Selvam R, Ashworth A, Robinson A, Digby GC.

Clin Lung Cancer. 2018 Jul;19(4):323-330.e3. doi: 10.1016/j.cllc.2018.02.001. Epub 2018 Feb 21. Review.

PMID:
29544716
24.

Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study.

Wright LB, Schoemaker MJ, Jones ME, Ashworth A, Swerdlow AJ.

Int J Cancer. 2018 Aug 15;143(4):782-792. doi: 10.1002/ijc.31364. Epub 2018 Mar 23.

25.

DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade.

Touat M, Sourisseau T, Dorvault N, Chabanon RM, Garrido M, Morel D, Krastev DB, Bigot L, Adam J, Frankum JR, Durand S, Pontoizeau C, Souquère S, Kuo MS, Sauvaigo S, Mardakheh F, Sarasin A, Olaussen KA, Friboulet L, Bouillaud F, Pierron G, Ashworth A, Lombès A, Lord CJ, Soria JC, Postel-Vinay S.

J Clin Invest. 2018 Apr 2;128(4):1671-1687. doi: 10.1172/JCI90277. Epub 2018 Mar 19.

26.

Commonly Occurring Cell Subsets in High-Grade Serous Ovarian Tumors Identified by Single-Cell Mass Cytometry.

Gonzalez VD, Samusik N, Chen TJ, Savig ES, Aghaeepour N, Quigley DA, Huang YW, Giangarrà V, Borowsky AD, Hubbard NE, Chen SY, Han G, Ashworth A, Kipps TJ, Berek JS, Nolan GP, Fantl WJ.

Cell Rep. 2018 Feb 13;22(7):1875-1888. doi: 10.1016/j.celrep.2018.01.053.

27.

Domestic light at night and breast cancer risk: a prospective analysis of 105 000 UK women in the Generations Study.

Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, Swerdlow AJ.

Br J Cancer. 2018 Feb 20;118(4):600-606. doi: 10.1038/bjc.2017.359. Epub 2018 Jan 23.

28.

Tracheostomy Insertion During Venovenous Extracorporeal Membrane Oxygenation: Do the Benefits Outweigh the Risks?

Charlesworth M, Szentgyorgyi L, Ashworth AD, Feddy L.

J Cardiothorac Vasc Anesth. 2018 Jun;32(3):e69-e70. doi: 10.1053/j.jvca.2017.12.021. Epub 2017 Dec 12. No abstract available.

PMID:
29336965
29.

Intravascular Folding of a Peripheral Venous VA-ECMO Cannula for Extracorporeal Cardiopulmonary Resuscitation.

Charlesworth M, Barker JM, Greenhalgh D, Garcia M, Szentgyorgyi L, Ashworth AD.

Artif Organs. 2018 Jan;42(1):104-105. doi: 10.1111/aor.13036. No abstract available.

PMID:
29314112
30.

The San Francisco Cancer Initiative: A Community Effort To Reduce The Population Burden Of Cancer.

Hiatt RA, Sibley A, Fejerman L, Glantz S, Nguyen T, Pasick R, Palmer N, Perkins A, Potter MB, Somsouk M, Vargas RA, van 't Veer LJ, Ashworth A.

Health Aff (Millwood). 2018 Jan;37(1):54-61. doi: 10.1377/hlthaff.2017.1260.

PMID:
29309234
31.

Reducing the Risk of Cardiac Perforation During Placement of Bicaval Veno-Venous Extracorporeal Membrane Oxygenation Cannulae.

Charlesworth M, Ashworth AD.

J Cardiothorac Vasc Anesth. 2018 Feb;32(1):e19-e20. doi: 10.1053/j.jvca.2017.09.003. Epub 2017 Sep 5. No abstract available.

PMID:
29217250
32.

Future cancer research priorities in the USA: a Lancet Oncology Commission.

Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A.

Lancet Oncol. 2017 Nov;18(11):e653-e706. doi: 10.1016/S1470-2045(17)30698-8. Epub 2017 Oct 31. Review.

33.

Decision-making in response to respiratory veno-venous extracorporeal membrane oxygenation referrals: is current practice precise enough?

Charlesworth M, Ashworth AD, Barker JM.

Anaesthesia. 2018 Feb;73(2):154-159. doi: 10.1111/anae.14155. Epub 2017 Nov 23. No abstract available.

PMID:
29168560
34.

Smoking and risk of breast cancer in the Generations Study cohort.

Jones ME, Schoemaker MJ, Wright LB, Ashworth A, Swerdlow AJ.

Breast Cancer Res. 2017 Nov 22;19(1):118. doi: 10.1186/s13058-017-0908-4.

35.

Authors' Response.

Gibbons JA, Ashworth A, Mojica AJ, Peele ME.

J Forensic Sci. 2017 Nov;62(6):1684-1686. doi: 10.1111/1556-4029.13635. No abstract available.

PMID:
29152804
36.

ATR Is a Therapeutic Target in Synovial Sarcoma.

Jones SE, Fleuren EDG, Frankum J, Konde A, Williamson CT, Krastev DB, Pemberton HN, Campbell J, Gulati A, Elliott R, Menon M, Selfe JL, Brough R, Pettitt SJ, Niedzwiedz W, van der Graaf WTA, Shipley J, Ashworth A, Lord CJ.

Cancer Res. 2017 Dec 15;77(24):7014-7026. doi: 10.1158/0008-5472.CAN-17-2056. Epub 2017 Oct 16.

37.

Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.

Chong IY, Aronson L, Bryant H, Gulati A, Campbell J, Elliott R, Pettitt S, Wilkerson P, Lambros MB, Reis-Filho JS, Ramessur A, Davidson M, Chau I, Cunningham D, Ashworth A, Lord CJ.

Gut. 2018 Oct;67(10):1780-1792. doi: 10.1136/gutjnl-2017-314408. Epub 2017 Aug 22.

38.

Structural basis for recruitment of BRCA2 by PALB2.

Oliver AW, Swift S, Lord CJ, Ashworth A, Pearl LH.

EMBO Rep. 2017 Jul;18(7):1264. doi: 10.15252/embr.201744508. No abstract available.

39.

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.

Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ.

Mol Cancer Ther. 2017 Sep;16(9):2022-2034. doi: 10.1158/1535-7163.MCT-17-0098. Epub 2017 Jun 15.

40.

Acamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxiety.

Schaefer TL, Davenport MH, Grainger LM, Robinson CK, Earnheart AT, Stegman MS, Lang AL, Ashworth AA, Molinaro G, Huber KM, Erickson CA.

J Neurodev Disord. 2017 Jun 12;9:6. doi: 10.1186/s11689-017-9184-y. eCollection 2017.

41.

Family history and risk of breast cancer: an analysis accounting for family structure.

Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ.

Breast Cancer Res Treat. 2017 Aug;165(1):193-200. doi: 10.1007/s10549-017-4325-2. Epub 2017 Jun 3.

42.

Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.

Nikkilä J, Kumar R, Campbell J, Brandsma I, Pemberton HN, Wallberg F, Nagy K, Scheer I, Vertessy BG, Serebrenik AA, Monni V, Harris RS, Pettitt SJ, Ashworth A, Lord CJ.

Br J Cancer. 2017 Jun 27;117(1):113-123. doi: 10.1038/bjc.2017.133. Epub 2017 May 23.

43.

Dietary nitrate and blood pressure: evolution of a new nutrient?

Ashworth A, Bescos R.

Nutr Res Rev. 2017 Dec;30(2):208-219. doi: 10.1017/S0954422417000063. Epub 2017 May 17. Review.

PMID:
28511731
44.

Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors.

Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY.

Cancer Discov. 2017 Sep;7(9):999-1005. doi: 10.1158/2159-8290.CD-17-0146. Epub 2017 Apr 27.

45.

Correction: CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours.

Costa-Cabral S, Brough R, Konde A, Aarts M, Campbell J, Marinari E, Riffell J, Bardelli A, Torrance C, Lord CJ, Ashworth A.

PLoS One. 2017 Apr 20;12(4):e0176578. doi: 10.1371/journal.pone.0176578. eCollection 2017. Erratum in: PLoS One. 2018 Oct 26;13(10):e0206729.

46.

The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine.

Ghazi Suliman MA, Ogungbenro K, Kosmidis C, Ashworth A, Barker J, Szabo-Barnes A, Davies A, Feddy L, Fedor I, Hayes T, Stirling S, Malagon I.

J Crit Care. 2017 Aug;40:113-118. doi: 10.1016/j.jcrc.2017.03.010. Epub 2017 Mar 12.

PMID:
28384599
47.

PARP inhibitors: Synthetic lethality in the clinic.

Lord CJ, Ashworth A.

Science. 2017 Mar 17;355(6330):1152-1158. doi: 10.1126/science.aam7344. Epub 2017 Mar 16. Review.

48.

Marked for death: targeting epigenetic changes in cancer.

Pfister SX, Ashworth A.

Nat Rev Drug Discov. 2017 Apr;16(4):241-263. doi: 10.1038/nrd.2016.256. Epub 2017 Mar 10. Review.

PMID:
28280262
49.

Tropomyosin Receptor Antagonism in Cylindromatosis (TRAC), an early phase trial of a topical tropomyosin kinase inhibitor as a treatment for inherited CYLD defective skin tumours: study protocol for a randomised controlled trial.

Cranston A, Stocken DD, Stamp E, Roblin D, Hamlin J, Langtry J, Plummer R, Ashworth A, Burn J, Rajan N.

Trials. 2017 Mar 7;18(1):111. doi: 10.1186/s13063-017-1812-z.

50.

Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells.

Pettitt SJ, Krastev DB, Pemberton HN, Fontebasso Y, Frankum J, Rehman FL, Brough R, Song F, Bajrami I, Rafiq R, Wallberg F, Kozarewa I, Fenwick K, Armisen-Garrido J, Swain A, Gulati A, Campbell J, Ashworth A, Lord CJ.

Sci Data. 2017 Mar 1;4:170020. doi: 10.1038/sdata.2017.20.

Supplemental Content

Loading ...
Support Center